NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial<
30 Aug 2023

SparingVision Reports Positive Initial Safety Data from the first cohort treated in its PRODYGY Phase I/II Gene Therapy Trial

Positive recommendation received from Data Safety Monitoring Board (DSMB) to dose second cohort

SparingVision Named a ‘Fierce 15’ Company by Fierce Biotech<
28 Aug 2023

SparingVision Named a ‘Fierce 15’ Company by Fierce Biotech

We are honored to be recognized among the prestigious Fierce 15 as a leading innovator in the biotech sector
Lava Therapeutics provides business update and reports second quarter 2023 financial results<
22 Aug 2023

Lava Therapeutics provides business update and reports second quarter 2023 financial results

Significant progress with lead program LAVA-1207 in mCRPC reaching dose level 8
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing<
14 Aug 2023

Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing

Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights<
09 Aug 2023

Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights

Strengthened Clinical and Regulatory Leadership Team with Key Appointments
Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update<
07 Aug 2023

Mineralys Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Continue enrolling subjects in ongoing pivotal Advance-HTN trial of lorundrostat, for the treatment of patients with uncontrolled or resistant hypertension

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update<
04 Aug 2023

KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED
Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference<
18 Jul 2023

Synendos Therapeutics AG Co-Founder and SAB Member, Professor Jürg Gertsch, Presents Groundbreaking New Findings on an Endocannabinoid Transporter at Cannabinoid Research Conference

Synendos investigates the therapeutic potential of this novel mode of action and Prof. Gertsch's pioneering research forms the basis of Synendos’ approach
Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)<
18 Jul 2023

Mineralys Therapeutics Announces Expansion of Planned Phase 2 Trial of Lorundrostat Alone and in Combination with SGLT2 Inhibitor to Treat Patients with Chronic Kidney Disease (CKD)

Trial to evaluate lorundrostat as a treatment for patients with Stage 2 to 4 chronic kidney disease

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics<
13 Jul 2023

SparingVision sells ex vivo GIRK technology to Tenpoint Therapeutics

SparingVision to receive equity, milestone payments, and royalties

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.